退伍军人健康系统二尖瓣手术10年结局与趋势
该研究比较美国退伍军人事务部(VA)医疗中心二尖瓣修复(MVRepair)与置换(MVReplace)的趋势与结局。2000至2013年共4165例手术,修复比例从48%升至63%(P<.001),中心间差异大。倾向匹配后总体30天和1年死亡率相似,但原发性退行性病变亚组修复长期死亡率更低(28% vs 37%,P=.003)。
要点
- VA系统二尖瓣手术死亡率低,修复比例10年间从48%升至63%。
- 倾向匹配后总体修复与置换的30天和1年死亡率相似。
- 原发性退行性二尖瓣反流亚组修复长期死亡率更低(28% vs 37%)。
核心结论
- VA系统二尖瓣手术死亡率低,修复在原发性二尖瓣反流中具生存优势但部分中心修复率低。
研究设计与样本
- 回顾性队列研究,纳入2000年10月至2013年10月40个VA医疗中心4165例二尖瓣手术患者(修复2408例,置换1757例)。
- 采用双变量分析、多因素logistic回归和倾向匹配分析总体及原发性退行性病变亚组。
主要发现
- 修复比例从2001年48%增至2013年63%(P<.001)。
- 中心手术量仅解释校正病例组合后修复率变异的19%(R2=0.19,P=.005)。
- 未校正30天死亡率修复3.5% vs 置换4.8%(P=.04),1年死亡率9.8% vs 12.1%(P=.02)。
- 倾向匹配总体队列(n=2520)30天和1年死亡率相似。
- 倾向匹配原发性退行性亚组(n=664)修复长期死亡率更低(28% vs 37%,P=.003),风险校正HR 0.78(95%CI 0.61-1.01)。
临床怎么用
- 在VA系统中,对原发性退行性二尖瓣反流应优先考虑修复以改善长期生存。
- 修复率低的中心存在质量改进空间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare mitral valve repair (MVRepair) and mitral valve replacement (MVReplace) trends in the Veterans Affairs (VA) Surgical Quality Improvement Program. METHODS: Trends were compared by bivariate analyses, followed by backward stepwise selection and multivariable logistic modeling to determine the effect of preoperative comorbidities and facility-level factors on MVRepair (vs MVReplace) rate. A subgroup analysis focused on patients who underwent elective surgery for isolated primary degenerative mitral regurgitation. Propensity matching was done in the overall and primary degenerative cohorts. RESULTS: From October 2000 to October 2013, 4165 veterans underwent MVRepair (n = 2408) or MVReplace (n = 1757) for MV disease of any cause at 40 VA medical centers (procedural volume, 0-29/y; median 7/y). The MVRepair percentage increased from 48% in 2001 to 63% in 2013 (P < .001). MVRepair rates varied widely among centers; center volume explained only 19% of this variation after adjustment for case mix (R2 = 0.19, P = .005). Unadjusted 30-day and 1-year mortality rates were lower after MVRepair than after MVReplace (3.5% vs 4.8%, P = .04; 9.8% vs 12.1%, P = .02). Among the propensity-matched patients (n = 2520), 30-day and 1-year mortality were similar after MVRepair and MVReplace. In the propensity-matched primary degenerative subgroup (n = 664), unadjusted long-term mortality for up to 10 years postoperatively was lower after MVRepair (28% vs 37%, P = .003), as was risk-adjusted long-term mortality (hazard ratio, 0.78; 95% confidence interval, 0.61-1.01). CONCLUSIONS: In the VA Health System, mortality after MV operations is low. Despite the survival advantage associated with MV repair in primary mitral regurgitation, repair is infrequent at some centers, representing an opportunity for quality improvement.
引用
- Bakaeen FG, Shroyer AL, Zenati MA, et al. Mitral valve surgery in the US Veterans Administration health system: 10-year outcomes and trends. J Thorac Cardiovasc Surg. 2017. PMID: 29074046. doi:10.1016/j.jtcvs.2017.07.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。